Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 10135-825

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 10135-825). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marlex Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

825-10 (825 10)

The text contains information about Venlafaxine Hydrochloride Extended-Release Capsules, USP. Each capsule contains 103.75 mg of Venlafaxine. It mentions standard dosage and storage conditions. It also refers to the medication for the treatment of depressive episodes, but the complete content appears to be not fully available.*

FDA Label Image

825-30 (825 30)

This text is a description of Venlafaxine Hydrochloride capsules, a medication used for the treatment of various conditions. The information includes details such as the dosage, storage instructions, manufacturer details, and the presence of 30 capsules in the package. It is important to follow the recommended dosage and storage guidelines provided for optimal effectiveness and safety of the medication.*

FDA Label Image

825-75 (825 75)

FDA Label Image

825-90 (825 90)

This text provides information about Venlafaxine Hydrochloride Extended-Release Capsules, USP. Each capsule contains venlafaxine hydrochloride, equivalent to 37.5 mg of venlafaxine. The usual dosage and storage instructions are also mentioned. The medication guide for each patient should be included with the package. The capsules are intended to be dispensed as a unit. The manufacturing and distribution details are for Mariex Pharmaceuticals in New Castle, DE.*

FDA Label Image

826-10 (826 10)

This text describes a medication named "Venlafaxine Hydrochloride Extended-Release Capsules, USP" containing 75mg per capsule. It mentions the recommended storage temperature (20° to 25°C) and advises not to use after the expiration date. It is intended for use as per accompanying prescribing information.*

FDA Label Image

826-30 (826 30)

This is a label for Venlafaxine Hydrochloride Extended-Release Capsules, USP, containing 75mg in each of the 30 capsules. The medication guide enclosed provides essential information for the patient. It is recommended to store the capsules at a temperature between 20°C to 25°C. The product is manufactured for/distributed by Marlex Pharmaceuticals, Inc. based in New Castle, DE. It is crucial to keep the medication out of reach and sight of children. For further details, refer to the accompanying prescribing information.*

FDA Label Image

826-75 (826 75)

This text is a description of Venlafaxine Hydrochloride Extended-Release Capsules, USP. It includes information for pharmacists on how to distribute the medication, the active ingredients, dosage instructions, storage recommendations, and manufacturer details. It also mentions the existence of a Medication Guide for further information.*

FDA Label Image

826-90 (826 90)

This is a description of Venlafaxine Hydrochloride Extended-Release Capsules, USP. The medication guide enclosed with the capsules provides information for the patient. Each capsule contains 75mg of venlafaxine. The usual dosage instructions are included in the prescribing information. The package is designed to be dispensed as a unit and should be stored at a temperature between 20° to 25°C (68° to 77°F). It is important to keep the capsules out of reach and sight of children. The medication is manufactured for and distributed by Marlex Pharmaceuticals, Inc.*

FDA Label Image

827-10 (827 10)

FDA Label Image

827-30 (827 30)

This text is about Venlafaxine Hydrochloride Extended-Release Capsules, USP. The pharmacist is instructed to dispense the enclosed medication guide to each patient. Each capsule contains venlafaxine hydrochloride, USP equivalent to 130 mg. The usual dosage information is provided in the accompanying prescribing information. The package is to be dispensed as a unit and should be stored at 20° to 25°C (68° to 77°F). It is manufactured for/distributed by Marlex Pharmaceuticals, Inc. in New Castle, DE.*

FDA Label Image

827-75 (827 75)

This is a label for Venlafaxine Hydrochloride Extended-Release Capsules, USP. Each capsule contains 150 mg of venlafaxine hydrochloride. The pharmacist is instructed to disperse the enclosed Medication Guide to each patient. It is recommended to store the capsules at 20° to 25°C (68° to 77°F). The package is designed to be dispensed as a unit containing 15 capsules. Manufactured for/Distributed by Marlex Pharmaceuticals, Inc.*

FDA Label Image

827-90 (827 90)

This text is a label for Venlafaxine Hydrochloride Extended-Release Capsules, USP, which contains 90 capsules. Each capsule contains Venlafaxine Hydrochloride equivalent to 130 mg. The medication is intended for a unit dose. It provides storage instructions, manufacturer information, and indicates that it is Rx only.*

FDA Label Image

Image (Dcddf00d F2f2 4044 B94a 13658bf2ab59 01)

FDA Label Image

Image (Dcddf00d F2f2 4044 B94a 13658bf2ab59 02)

FDA Label Image

Image (Dcddf00d F2f2 4044 B94a 13658bf2ab59 03)

This is a list of drug interactions showing the fold change and 90% confidence intervals in pharmacokinetics (PK) of various drugs when combined with venlafaxine. The text discusses how the levels of different drugs such as ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium change when taken in combination with venlafaxine. The table provides insights into how the maximum concentration (Cmax) and area under the curve (AUC) of these drugs are affected when interacting with venlafaxine.*

FDA Label Image

Image (Dcddf00d F2f2 4044 B94a 13658bf2ab59 04)

This document lists a variety of drugs and their interactions, as well as information on analytes, PK parameters, fold change, and 90% CI values. The drugs mentioned include Ethanor, Diazepam, Alprazolam, Indinavir, Metoprolol, Risperidone, Imipramine, Haloperidol, Caffeine, Tolbutamide, and Lithium. The text also refers to various metabolites and active moieties of these drugs. Additionally, it presents PK parameters such as Cmax and AUC, along with potential fold changes relative to a reference value.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.